Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Opexa Therapeutics Inc.

Division of Acer Therapeutics Inc.
www.opexatherapeutics.com

Latest From Opexa Therapeutics Inc.

Biopharma Quarterly Dealmaking Statistics, Q3 2017

Third-quarter biopharma financing, which totaled $12.5 billion, was dominated by follow-on public offerings, which represented virtually half the value. Acquisition activity was headlined by a major move by Gilead in the CART market. Five alliances were signed worth over $1 billion, led by a partnership between two key players, Merck & Co. and AstraZeneca.

BioPharmaceutical Deals

Start-Up Quarterly Statistics: Fundraising Fell, But Deal-Making Rose In Q3

A review of biopharma start-up deal-making and financing activity from July through September 2017, based on data from Strategic Transactions, showed that fundraising declined 18% from the previous quarter, however the number of acquisitions doubled to eight.

StartUps and SMEs Financing

Deals Shaping The Medical Industry, October 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2017.

Deals BioPharmaceutical

Pipeline Watch: Phase III Results For New Antibiotics And Long-Acting HIV/AIDS Biologic

Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Alias(es)
  • PharmaFrontiers Corp.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Acer Therapeutics Inc.
  • Senior Management
  • Neil K Warma, Pres. & CEO
    Don Healey, PhD, CSO
    Donna R Rill, Chief Development Officer
  • Contact Info
  • Opexa Therapeutics Inc.
    Phone: (281) 775-0600
    2635 Technology Forest Blvd.
    The Woodlands, TX 77381
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register